Newsroom

November 2016

• 
  Story Nov 29, 2016 Discovery

  Women in Science: Lilli Petruzzelli

  A lung cancer researcher describes her journey toward a career in science at Novartis.

• Press release Nov 29, 2016

  Novartis Access communique son bilan à un an et annonce la signature d'un protocole d'accord avec le Rwanda

  Le Rwanda devient le troisième pays à lancer Novartis Access, un programme de distribution de médicaments pour traiter les maladies chroniques dans les pays à faible revenu. Les premières livraisons…
• Press release Nov 29, 2016

  Novartis Access shares one-year learnings and announces memorandum of understanding with Rwanda

  Rwanda becomes third country to launch Novartis Access portfolio against chronic diseases with first deliveries planned in early 2017 Since September 2015, Novartis Access has delivered more than…
• Press release Nov 29, 2016

  Novartis Access informiert über Erfahrungen im ersten Jahr und gibt Memorandum of Understanding mit Ruanda bekannt

  Ruanda ist das dritte Land, welches das Portfolio von Novartis Access gegen chronische Krankheiten einführen wird. Die ersten Medikamentenlieferungen sind für Anfang 2017 geplant. Seit September…
• In The News Nov 28, 2016

  Novartis Access one-year report

  The Novartis Access one-year report describes first results, early learnings and challenges from our first twelve months on the ground. It also includes external perspectives and country updates,…
• In The News Nov 28, 2016

  Tackling chronic disease with Novartis Access

  Chronic diseases like high blood pressure and diabetes impact more than just wealthy nations. Through the Novartis Foundation and Novartis Access, we’re working to address the rising threat of…
• 
  Story Nov 22, 2016 Discovery

  Women in Science: Hannah Mosca

  Oncology Regulatory Affairs Leader Hannah Mosca describes her lifelong interest in science and math, and what it’s like to work at Novartis

• Press release Nov 21, 2016

  Novartis acquires Selexys Pharmaceuticals Corporation and SelG1 antibody for reduction of pain crises in sickle cell disease (SCD)

  Deal followed results of Phase II SUSTAIN study of SelG1 in reduction of vaso-occlusive pain crises, a major complication of SCD with limited treatment options  Results of SUSTAIN will be…
• Press release Nov 21, 2016

  Novartis commends publication of major report which recommends broad use of dual bronchodilators to treat COPD

  2017 GOLD report recommends the first-line use of dual bronchodilators, such as Ultibro® Breezhaler®, in the treatment of the majority of symptomatic COPD patients  Bronchodilation regarded…
• Press release Nov 18, 2016

  Innovative study with three treatment switches confirms Sandoz biosimilar etanercept has equivalent efficacy to originator

  No clinically meaningful differences between biosimilar etanercept and the originator product in safety and efficacy over 52 weeks[1]  Innovative study design demonstrates switching between…
• Press release Nov 16, 2016

  Novartis announces AMG 334 significantly reduces monthly migraine days in second pivotal Phase III episodic migraine study

  STRIVE, the first six-month placebo-controlled study of AMG 334 (erenumab) in migraine, met the primary endpoint, showing a statistically significant reduction in monthly migraine days versus…
• Press release Nov 16, 2016

  Novartis data at ASH and SABCS showcase latest innovations in development for patients with blood disorders and breast cancer

  First results from global registrational trial of CAR T therapy, CTL019, in pediatric relapsed/refractory acute lymphoblastic leukemia  Sub-group analyses from pivotal MONALEESA-2 trial of…